That equation led Vyvgart, argenx’s treatment for generalized myasthenia gravis (gMG), to take the top spot, with an overall score of 3.9. Cabenuva, GSK’s long-acting HIV treatment ...

which allows for a once-weekly injection administered by a healthcare professional that takes between 30 and 90 seconds, rather than a weekly, hour-long IV infusion delivered at a clinic with Vyvgart.

hour-long IV infusion delivered at a clinic. Combined, the two drugs made $816 million in sales in the first nine months of the year, putting the Vyvgart franchise well on course to top the $1 ...

Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and VYVGART Hytrulo gMG patients on VYVGART achieve rapid, substantial, and sustained efficacy ...

Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and VYVGART Hytrulo gMG patients on VYVGART achieve rapid, substantial, and sustained efficacy ...

CEO Tim Van Hauwermeiren emphasized 2024 as a "phenomenal year," highlighted by expanding the reach of VYVGART to over 10,000 patients globally across three approved indications. He noted the ...

Argenx (ARGX) announced clinical trial and real-world data for Vyvgart and Vyvgart Hytrulo will be presented at the American Academy of Neurology annual meeting, taking place in San Diego ...

Argenx (NASDAQ:ARGX) has received FDA approval for Vyvgart Hytrulo for the treatment of adults with chronic inflammatory demyelinating polyneuropathy, or CIDP. The Dutch biotech company said the ...

Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, ...